The trial comprised an initial safety run-in using abituzumab doses up to @ mg combined with a standard of care ( SoC : cetuximab plus irinotecan ) and a phase II part in which patients were randomised @ : @ : @ to receive abituzumab @ mg ( arm A ) or @ mg ( arm B ) every @ weeks combined with SoC , or SoC alone ( arm C ) .